Atomoxetine Beyond ADHD: A Fact or Aritfact

Abstract

Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics